Loading...
Back to narrative

FDA Clearance And New Deployments Will Expand Non-Invasive Sleep Care

VVOS logo
VVOS
AnalystConsensusTarget
Not Invested
Published 15 Apr 2025

Update shared on22 Aug 2025

Fair value Increased 21%
Previous
AnalystConsensusTarget's Fair Value
US$5.10
15.1% undervalued intrinsic discount
28 Aug
US$4.33
Loading
1Y
59.8%
7D
3.1%

The sharp upward revision in the analyst price target for Vivos Therapeutics reflects markedly improved revenue growth forecasts and a lower future P/E multiple, raising fair value from $4.22 to $5.10.


What's in the News


  • Vivos Therapeutics will be unable to file its next 10-Q by the SEC deadline.
  • A multicenter clinical trial published in the European Journal of Pediatrics showed positive safety and efficacy results for Vivos' DNA device in treating pediatric OSA, supporting previous FDA clearance and offering a non-invasive alternative to surgery.
  • SP Manager LLC announced intentions to engage Vivos Therapeutics on financial performance, strategy, operations, and governance.
  • Following Moss Adams LLP’s merger with Baker Tilly US, LLP, Vivos appointed Baker Tilly as its new auditor; previous audit opinions from Moss Adams were unqualified but included a going concern uncertainty.

Valuation Changes


Summary of Valuation Changes for Vivos Therapeutics

  • The Consensus Analyst Price Target has significantly risen from $4.22 to $5.10.
  • The Consensus Revenue Growth forecasts for Vivos Therapeutics has significantly risen from 12.5% per annum to 39.4% per annum.
  • The Future P/E for Vivos Therapeutics has significantly fallen from 32.13x to 26.59x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.